CSL 0.91% $308.87 csl limited

As a bit of a background The Australian Red Cross Blood Service...

  1. 2,270 Posts.
    lightbulb Created with Sketch. 51
    As a bit of a background The Australian Red Cross Blood Service (ARCBS) was very much the shopfront for CSL in Australia for the collection of blood ostensibly for the purpose of 'saving lives'. Under early arrangements the ARCBS were paid quite handsomely for the donated blood product, of which a small quantity of that collected being available for transfusion related requirement with the larger portion being sold off as 'Red Gold' to CSL for processing into highly marketable blood products i.e. factor 8 factor 9. The financial process has since changed which has created opacity with respect to financial arrangements between CSL and ARCBS.

    With respect to the UK it is blood product that CSL is involved with . CSL Behring (originally formed from the acquisition of Aventis Behring that was then amalgamated with ZLB Bioplasma initially as ZLB Behring and later re branded CSL Behring about 2003/4) Amongst the products used in the UK is product now called 'Voncento', human coag factor 8 which has demand by haemophiliacs.

    https://www.cslbehring.co.uk/products/product-range

    Quite sadly in Australia many Haemophiliacs and other recipients ended up receiving contaminated blood and blood products as in the UK in the past.
    For an interesting perspective on thisAustralian Author Bryce Courtney wrote a book titled 'April fools Day' Bryce's son, a haemophiliac, passed away as a result of contaminated Blood Product
 
watchlist Created with Sketch. Add CSL (ASX) to my watchlist
(20min delay)
Last
$308.87
Change
-2.830(0.91%)
Mkt cap ! $149.6B
Open High Low Value Volume
$309.97 $311.31 $308.00 $27.83M 89.96K

Buyers (Bids)

No. Vol. Price($)
5 40 $308.87
 

Sellers (Offers)

Price($) Vol. No.
$308.88 36 9
View Market Depth
Last trade - 12.58pm 22/07/2024 (20 minute delay) ?
CSL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.